Pharmacist-led Smoking-Cessation Services in the United States - A Multijurisdictional Legal Analysis.

Innovations in Pharmacy Pub Date : 2022-04-02 eCollection Date: 2022-01-01 DOI:10.24926/iip.v13i1.4643
Landon S Bordner, Joseph Lavino
{"title":"Pharmacist-led Smoking-Cessation Services in the United States - A Multijurisdictional Legal Analysis.","authors":"Landon S Bordner,&nbsp;Joseph Lavino","doi":"10.24926/iip.v13i1.4643","DOIUrl":null,"url":null,"abstract":"<p><p>A challenge presents itself when pharmacy students and pharmacists have the knowledge, skills, and abilities to provide optimal patient care, which can prevent the healthcare industry from incurring expenditures reaching billions of dollars annually from chronic and acute disease state management, yet due to the lack of statutory or regulatory authority to independently prescribe and dispense smoking cessation products they are unable to tap into this potential. Prescriptive authority of pharmacists is not a novel concept; however, State Legislatures and Boards of Pharmacy have been slow to expand upon the pharmacist's scope of practice to include this authority. As a consequence, this inaction hinders the opportunity of almost 21.5 million patients, who attempt to quit smoking annually, the ability to access a U.S. Food and Drug Administration approved, evidence-based medication-assisted or nicotine replacement therapy prescribed by a pharmacist.<sup>2</sup> Current legislative efforts, laws, and regulations regarding a pharmacist's prescriptive authority for tobacco cessation therapy vary greatly amongst the states and do not include reference to e-cigarettes or electronic nicotine delivery systems (e.g., e-cigs, vape pens, vapes, mods, etc.). Additionally, pharmacists are often required to practice under a statewide protocol or enter into a collaborative practice agreement (\"CPA\") with a designated physician, which are often complex and create significant barriers for the pharmacist to practice at the top of their license and for the benefit of the patient. This legal and regulatory study reveals the following: 1) Those States that have addressed or attempted to address the pharmacist's prescriptive authority for tobacco cessation therapy, 2) the authority to independently prescribe vs. practice under a statewide protocol, 3) the products able to be prescriber or dispensed under the pharmacist's prescriptive authority or statewide protocol, and 4) the guidelines and/or protocols referenced within their respective State laws and regulations. States and their residents would benefit greatly from amending their laws and regulations to expand upon the pharmacist's prescriptive authority, granting them the ability to help their communities by performing services they are highly trained to perform.</p>","PeriodicalId":13646,"journal":{"name":"Innovations in Pharmacy","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c2/1e/21550417-13-01-4643.PMC9598971.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Innovations in Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24926/iip.v13i1.4643","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

A challenge presents itself when pharmacy students and pharmacists have the knowledge, skills, and abilities to provide optimal patient care, which can prevent the healthcare industry from incurring expenditures reaching billions of dollars annually from chronic and acute disease state management, yet due to the lack of statutory or regulatory authority to independently prescribe and dispense smoking cessation products they are unable to tap into this potential. Prescriptive authority of pharmacists is not a novel concept; however, State Legislatures and Boards of Pharmacy have been slow to expand upon the pharmacist's scope of practice to include this authority. As a consequence, this inaction hinders the opportunity of almost 21.5 million patients, who attempt to quit smoking annually, the ability to access a U.S. Food and Drug Administration approved, evidence-based medication-assisted or nicotine replacement therapy prescribed by a pharmacist.2 Current legislative efforts, laws, and regulations regarding a pharmacist's prescriptive authority for tobacco cessation therapy vary greatly amongst the states and do not include reference to e-cigarettes or electronic nicotine delivery systems (e.g., e-cigs, vape pens, vapes, mods, etc.). Additionally, pharmacists are often required to practice under a statewide protocol or enter into a collaborative practice agreement ("CPA") with a designated physician, which are often complex and create significant barriers for the pharmacist to practice at the top of their license and for the benefit of the patient. This legal and regulatory study reveals the following: 1) Those States that have addressed or attempted to address the pharmacist's prescriptive authority for tobacco cessation therapy, 2) the authority to independently prescribe vs. practice under a statewide protocol, 3) the products able to be prescriber or dispensed under the pharmacist's prescriptive authority or statewide protocol, and 4) the guidelines and/or protocols referenced within their respective State laws and regulations. States and their residents would benefit greatly from amending their laws and regulations to expand upon the pharmacist's prescriptive authority, granting them the ability to help their communities by performing services they are highly trained to perform.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
药剂师主导的戒烟服务在美国-多司法管辖区的法律分析。
当药学专业的学生和药剂师拥有提供最佳患者护理的知识、技能和能力时,挑战就出现了,这可以防止医疗保健行业每年因慢性和急性疾病状态管理而产生数十亿美元的支出,但由于缺乏独立开处方和分发戒烟产品的法定或监管机构,他们无法利用这一潜力。药师的处方权威并不是一个新概念;然而,州立法机构和药学委员会在扩大药剂师的实践范围以包括这一权力方面进展缓慢。因此,这种不作为阻碍了每年近2150万试图戒烟的患者获得美国食品和药物管理局批准的、基于证据的药物辅助疗法或药剂师处方的尼古丁替代疗法的机会目前各州关于药剂师对戒烟治疗的规定权力的立法努力、法律和法规差别很大,不包括电子烟或电子尼古丁输送系统(例如,电子烟、电子烟笔、电子烟、电子烟等)。此外,药剂师通常被要求在全州范围内的协议下执业,或者与指定的医生签订合作执业协议(“CPA”),这通常是复杂的,并且为药剂师在他们的执照上执业和为患者造福创造了重大障碍。这项法律和监管研究揭示了以下内容:1)那些已经解决或试图解决药剂师在戒烟治疗方面的规定性权威的州;2)在全州协议下独立开处方的权力与实践的权力;3)根据药剂师的规定性权威或全州协议可以开处方或分发的产品;以及4)各自州法律法规中引用的指南和/或协议。各州及其居民将从修改其法律和法规中获益良多,以扩大药剂师的规定权力,使他们有能力通过执行他们受过严格训练的服务来帮助他们的社区。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Undergraduate Student Perceptions of Pharmacy Entrustable Professional Activities Strategies Proposed by Students and Pharmacists for Virtual Experiential Patient Care Practicums In-class Exercises Regarding the Roles of Excipients in a Pharmaceutics Course The Impact of Antimicrobial Stewardship in Treating Patients with Escherichia coli Bacteremia in a Small Single Center Community Hospital Development and Pilot Testing of the OTC Coach Software to Support Student Pharmacist Learning
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1